1-Methylnicotinamide is formed in the body during the metabolism of niacin (vitamin B3) The applicant suggests that 1-Methylnicotinamide, in food supplements, would be used to reduce risk factors related to the progression of atherosclerosis. Claims for this use will require approval under EU nutrition and health claims legislation.
1-Methylnicotinamide is also a novel food and before any new food product can be introduced on the European market, it must be rigorously assessed for safety. In the UK, the assessment of novel foods is carried out by an independent committee of scientists appointed by the Food Standards Agency, the Advisory Committee on Novel Foods and Processes (ACNFP)
Any comments on the draft initial opinion should be emailed to the ACNFP secretariat at firstname.lastname@example.org by Monday 10 August 2015. Comments will be passed to the committee before it finalises its opinion on this novel food ingredient.
All views/comments received by the ACNFP will be made available for public examination as part of the Committee's consideration of the dossier. If you would prefer your comments not to be made publicly available, please indicate this in your response.